Xu Yang, Fan Yuying, Liu Sijin, Chang Jianmei, Guo Caifeng, Chen Lanhui, Guo Wenzheng, Dang Jinwen, Wang Hongwei, Tan Yanhong
Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Front Oncol. 2024 Dec 12;14:1518387. doi: 10.3389/fonc.2024.1518387. eCollection 2024.
The coexistence of three or more transcripts in one patient with chronic myeloid leukemia (CML) is rarely reported. Thus, the disease progression and drug response are still unknown. This case report aimed to explore the drug response of CML with variant transcripts and to enrich the clinical treatment of rare types of CML. A 66-year-old Chinese female patient was diagnosed with chronic myeloid leukemia-chronic phase (CML-CP) expressing four transcripts, including variant e16a2(V-e16a2), variant e13a2(V-e13a2), classical e13a2, and e14a2 transcripts. The patient was treated with flumatinib, a tyrosine kinase inhibitor (TKI).The variant transcripts reported exhibited a favorable response to TKI, and attention should be directed toward monitoring variant transcripts.
一名慢性髓性白血病（CML）患者体内同时存在三种或更多转录本的情况鲜有报道。因此，疾病进展和药物反应仍不明确。本病例报告旨在探讨具有变异转录本的CML的药物反应，并丰富罕见类型CML的临床治疗经验。一名66岁的中国女性患者被诊断为慢性髓性白血病慢性期（CML-CP），表达四种转录本，包括变异型e16a2（V-e16a2）、变异型e13a2（V-e13a2）、经典型e13a2和e14a2转录本。该患者接受了酪氨酸激酶抑制剂（TKI）氟马替尼治疗。报道的变异转录本对TKI表现出良好反应，应关注对变异转录本的监测。
